Skip to main content

Health industry representatives questioned on Cancer Drugs Fund

27 November 2015

Public Accounts Committee takes evidence to assess the effectiveness of the Cancer Drugs Fund.

Witnesses

Monday 30 November 2015, Committee Room 15, Palace of Westminster

At 4pm

  • Mark Hicken, Managing Director, Johnson and Johnson
  • Deb Lancaster, Director of Market Access, Roche
  • Harpal Kumar, Chief Executive, Cancer Research UK

At 4.30pm

  • Will Cavendish, Director General, Innovation, Growth and Technology, Department of Health
  • Simon Stevens, Chief Executive, NHS England
  • Professor Peter Clark, Chair of the Cancer Drugs Fund, NHS England
  • Sir Andrew Dillon, Chief Executive, National Institute for Health and Clinical Excellence

Purpose of session

This session challenges the Department of Health and NHS England on the lack the data available to assess the effectiveness of the Cancer Drugs Fund and whether it is the best way to care for patients, and how Department, NHS England, NICE and pharmaceutical companies can work together to ensure the Cancer Drugs Fund is sustainable.

Further information 

Image: iStockphoto

Video: Parliamentary copyright